Tests finerenone in people hospitalized with heart failure and preserved heart pumping
Compares finerenone with placebo in adults hospitalized for acute decompensated heart failure.
Plain-language title generated from the registry record
Registry title: A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Key facts
- Where
- Lima, PeruSee the 7 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital, or recently discharged, with heart failure and a mildly reduced or preserved heart pumping function. Finerenone is compared with placebo.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Hospitalized with heart failure now, or discharged within the last 30 days, with signs and symptoms of heart failure at admission. Heart pumping function (ejection fraction) on imaging is 40% or higher.
- Earlier treatment
- Cannot join if on or planning long-term treatment with a mineralocorticoid receptor antagonist (MRA).
- Biomarker or test result
- High NTproBNP or BNP blood level. Without atrial fibrillation: NTproBNP 500 pg/mL or more, or BNP 125 pg/mL or more. With atrial fibrillation: NTproBNP 1500 pg/mL or more, or BNP 375 pg/mL or more.
Main reasons for not taking part
- Long-term treatment with an MRA, now or planned
- Past severe high potassium while using an MRA
- Kidney function (eGFR) below 25 mL/min/1.73m² or potassium above 5.0 mmol/L at screening
- Heart attack, heart procedure or device implant within 30 days
- Severe uncorrected heart valve disease, or another likely cause of the heart failure symptoms
Read by machine on 9 November 2026.
Where in Peru
- LimaHospital not named in the registryTaking people
- LimaHospital not named in the registryTaking people
- LimaHospital not named in the registryTaking people
- LimaHospital not named in the registryTaking people
- Lima, Lima ProvinceHospital not named in the registryTaking people
- LimaHospital not named in the registryTaking people
- LimaHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Colorado Prevention Center
- Trial code
- NCT06008197
- Record updated
- 10 September 2026
- Original description
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.Read full original descriptionShow less
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
Inclusion: Provide written informed consent; Age ≥18 years or legal age of majority if >18 years in the participant's country of residence; Current hospitalization or recently discharged (during or within 30 days of discharge) with the primary diagnosis of heart failure; Heart failure signs and symptoms at the time of hospital admission; Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher); Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg/mL or B-type natriuretic peptide (BNP) ≥125 pg/mL for patients without atrial fibrillation (AF); or elevated NTproBNP ≥1500 pg/mL or BNP ≥375 pg/mL for patients with AF.
Exclusion: Current or planned long-term treatment with a mineralocorticoid receptor antagonist (MRA); Documented prior history of severe hyperkalemia in the setting of MRA use; Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers; Acute myocardial infarction due to plaque rupture, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days; Hemodynamically significant (severe) uncorrected primary cardiac valvular disease; Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or known pericardial constriction; Probable alternative cause of participant's heart failure symptoms; Known hypersensitivity to the IP (active substance or excipients); Estimated glomerular filtration rate (eGFR) <25 mL/min/1.73m² or potassium >5.0 mmol/L at screening.